Skip to Content
Find More Like This
Return to Search


United States Patent Application

View the Complete Application at the US Patent & Trademark Office
Lawrence Berkeley National Laboratory - Visit the Technology Transfer and Intellectual Property Management Department Website
It is proposed that cancer cells express SATB1, and that SATB1 acts as a determinant for the acquisition of metastatic activity by controlling expression of a specific set of genes that promote metastatic activity. In order for cancer cells to gain the ability to metastasize, SATB1 re-organizes or re-packages genomic sequences in a specific manner to allow a switch in the pattern of gene expression. SATB1 expression was found restricted mainly to aggressive cancer cells where it may regulate the genetic and epigenetic changes that program the steps involved in the metastatic process. The present invention describes reagents and tools to detect the SATB1 protein for use in diagnosis and prognosis of aggressive cancers and therapeutics to inhibit SATB1 protein to deplete its expression in metastatic and aggressive cancers.
Kohwi-Shigematsu, Terumi (El Cerrito, CA), Han, Hye-Jung (Albany, CA), Kohwi, Yoshinori (El Cerrito, CA)
14/ 540,991
November 13, 2014
STATEMENT OF GOVERNMENTAL SUPPORT [0002] This invention was made during work supported by the U.S. Department of Energy at Lawrence Berkeley National Laboratory under Contract No. DE-AC02-05CH11231 and Grant No. R37 CA039681 awarded by the National Institutes of Health/National Cancer Institute. The government has certain rights in this invention.